Report finds growing pains for rare disease drugs, but local biotechs buck trend

For the second year in a row, Waltham-based consulting firm Trinity Partners found that orphan and ultra-orphan treatments stumbled out of the gate and have failed to find their footing after three years of sales. But some local biotechs bucked the trend.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news